BaseSpace
Correlation Engine 2.0
Import Your Data
Literature

FAQ

More FAQs

Back to top
Clear Search sequence regions
(e.g. Lovastatin, rs2300478, KLK3, Metabolism of xenobiotics, Inflammatory disorder, Liver)
Bookmark Forward

Selective SIRT2 inhibitors as promising anticancer therapeutics: An update from 2016 to 2020.

Eslam Roshdy, Muhamad Mustafa, Abd El-Rahman Shaltout, Mohamed O Radwan, Mahmoud A A Ibrahim, Mahmoud E Soliman, Mikako Fujita, Masami Otsuka, Taha F S Ali

European journal of medicinal chemistry 2021 Nov 15


filter terms:
  • drug antitumor (1)
  • human (2)
  • protein human (1)
  • regulates (1)
  • SIRT2 (9)
  • sirt2 protein, human (1)
  • sirtuins (1)
    • Sizes of these terms reflect their relevance to your search.

    Sirtuin 2 (SIRT2) is a member of the human sirtuins, which regulates various biological processes and is deemed as a novel biomarker for different cancers. Depending on the tumor type, SIRT2 knockout leads to a controversial role in tumorigenesis, however, pharmacological inhibition of SIRT2 results exclusively in growth inhibition of various cancer cells. In this respect, selective SIRT2 inhibitors hold therapeutic promise in a wide range of tumors. The literature has a batch of successful stories of SIRT2 modulators discovery. This review presents our perspective on the up-to-date selective SIRT2 inhibitors and their antiproliferative activity. Copyright © 2021 Elsevier Masson SAS. All rights reserved.

    Citation

    Eslam Roshdy, Muhamad Mustafa, Abd El-Rahman Shaltout, Mohamed O Radwan, Mahmoud A A Ibrahim, Mahmoud E Soliman, Mikako Fujita, Masami Otsuka, Taha F S Ali. Selective SIRT2 inhibitors as promising anticancer therapeutics: An update from 2016 to 2020. European journal of medicinal chemistry. 2021 Nov 15;224:113709

    Expand section icon Mesh Tags

    Expand section icon Substances


    PMID: 34303869

    View Full Text
    • Copyright © 2023 Illumina Inc. All rights reserved.